Diversity Action Plans for Clinical Trials: Evaluating FDA’s Draft Guidance

(MedPage Today) — The FDA is intent on improving the enrollment of participants — also known as “subjects” — from underrepresented populations in clinical studies for drugs and devices. The FDA’s initiative is not unlike the attempts of…

Powered by WPeMatico